Semaglutide Side Effects: A Clinical Reference for India

How common are the gastrointestinal side effects, specifically?

Nausea is the single most frequent among semaglutide side effects reported in the STEP trial programme, reported in 43.9% of trial participants on the 2.4 mg dose versus 16.1% on placebo, across the pooled STEP trial programme for weight management. Diarrhoea, vomiting and constipation follow at meaningfully lower but still elevated rates against placebo.

Diarrhoea occurred in 29.7% of semaglutide participants versus 15.9% on placebo, vomiting in 24.5% versus 6.3%, and constipation in 24.2% versus 11.1%. The large majority of these events, over 98%, were mild-to-moderate and transient, clustering around dose-escalation steps rather than persisting at a flat rate through treatment. Trial-reported semaglutide side effects therefore skew heavily toward transient GI intolerance rather than a fixed daily burden.

Do the GI side effects cause people to stop the drug?

Only a minority. Just 4.3% of semaglutide-treated participants in the pooled STEP analysis permanently discontinued treatment specifically because of a gastrointestinal adverse event, despite how common those events were overall. This tells a prescriber that tolerability, while genuinely unpleasant for many patients, rarely forces a full stop, and that most reported semaglutide side effects resolve well before a patient reaches for an alternative.

Slower dose titration is the standard clinical response to GI intolerance rather than early discontinuation, since most events cluster at each step-up in dose. Separately, gastrointestinal side effects contributed less than one percentage point to the total weight loss seen in trials, meaning the nausea is not the mechanism doing the clinical work.

What are the serious, low-frequency warnings on the label?

Acute pancreatitis, including necrotizing pancreatitis reported post-approval, sometimes fatal, appears on semaglutide's FDA prescribing information as a warning requiring prompt evaluation of persistent severe abdominal pain. Ileus and severe constipation with impaction were added to the label as a specific 2023 update, reflecting real post-marketing reports rather than a trial-only finding.

A boxed warning covers thyroid C-cell tumours, including medullary thyroid carcinoma, based on findings in rodent studies at clinically relevant exposures; the FDA label itself states that human relevance of this rodent finding is unknown and has not been established or ruled out by clinical or nonclinical data. This is precisely why semaglutide carries a contraindication in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, a decision for the prescribing physician, never a patient's own judgment call.

What is semaglutide's regulatory and market position in India right now?

Novo Nordisk's semaglutide patent in India expired in March 2026, opening the molecule to generic competition after Ozempic and Wegovy had already entered the Indian market as branded injections. Launch pricing ran from roughly ₹1,415 per weekly Ozempic dose to around ₹6,500 per Wegovy 2.4 mg dose, and over 40 domestic manufacturers are now preparing generic versions.

CDSCO has separately approved Wegovy specifically for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis, the first global approval of a GLP-1 receptor agonist for that specific indication. Rybelsus, the oral semaglutide formulation, remains approved in India only for type 2 diabetes; it does not carry a weight-management indication in India even though the US FDA cleared an oral weight-management use in 2025.

What interactions and precautions actually matter clinically?

Semaglutide slows gastric emptying, which is the mechanistic reason it can alter the absorption timing of orally administered drugs taken alongside it, a genuine consideration for any patient on a narrow-therapeutic-index oral medication. It also potentiates hypoglycaemia risk when combined with insulin or a sulfonylurea, requiring dose review of those agents rather than simply adding semaglutide on top.

Patients with a history of diabetic retinopathy warrant monitoring for retinopathy complications during rapid glycaemic improvement, a documented finding from cardiovascular outcome trials in the diabetes population specifically. None of this is a substitute for an individual medication review; it is the short list of interaction classes a prescribing physician should already be screening for before adding semaglutide to an existing regimen.

Why does reliable in-hospital stocking matter more for a drug like this?

Semaglutide is a chronic-therapy injection, not a one-time prescription, and a patient who can't refill a weekly dose inside the hospital pharmacy where they're already being monitored typically fills it at whichever outside chemist has stock that week, often a different brand or formulation than what was actually prescribed. That is a genuine continuity-of-care problem for a drug with a titration schedule and monitoring requirements attached to it.

It is also, plainly, a lost revenue stream on every refill that walks out the door instead of staying inside the hospital's own pharmacy. Medyzen's managed hospital pharmacy services piece covers how a hospital builds reliable stocking for exactly this kind of recurring, high-value prescription, the prescription leakage piece covers what that leakage costs across a patient's full treatment course, and our pharmacy inventory management guide covers the reorder discipline a weekly-injection drug like this actually needs.

Sources

1. 1WEGOVY (semaglutide) injection — full prescribing information — U.S. Food and Drug Administration
2. 2Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg — PubMed, National Library of Medicine
3. 3Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine
4. 4Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 — Nature Medicine
5. 5Central Drugs Standard Control Organisation — approvals and notifications, Government of India

This article is a clinical reference for physicians and hospital administrators. It is for informational purposes, is not a substitute for professional medical advice, and contains no dosage or treatment recommendation for patient self-use. Consult a qualified doctor for any individual clinical decision.